A new malaria vaccine developed by scientists at Oxford University, according to the results of the essay published on early September 28, 2022, was effective up to 80 %in the prevention of diseases in young children. This new vaccine, called R21, is a potentially improved version of another vaccine called RTS, which is approved by the World Health Organization for extensive use in regions with significant malaria contamination last October. RTS, S was the first vaccine for a human parasite infection.
RTS also showed high activity in limited examples in early tests, but in a more real-world environment-in the gas 3 clinical experiments, both estimated and observed activity was close to 40 %and 50 %. When you gave the vaccine, it turned out that the vaccine affects the effectiveness of the vaccine according to the infection season. In many countries, malaria typically peaked in the rainy season with more stagnant waters where mosquitoes can grow. In a recent study by Brian Greenwood from the London School of Hygiene and Tropical Medicine and his colleagues, an RTS, which was done just before the transmission season in West Africa, found that the S vaccine was extremely high.
For R21, only 450 months of 5-17 months were included in a recent study in Burkina Faso, where malaria infections were seasonal. The study showed that the first three doses of the vaccine and then a year later, reinforcement dose was effective up to 80 %in preventing infection.
Source:
https://www.hsph.harvard.edu/news/features/is-new-malaria-vaccine-world-changing-maybe/
